AstraZeneca`s Dapagliflozin gets DCGI nod for treatment of heart failure patients
(WorldNews Business)

New Delhi, Jul 4 (PTI) Drug firm AstraZeneca Pharma India on Saturday said it has received approval from Drugs Controller General of India (DCGI) for Dapagliflozin tablets fortreatment of patients suffering from heart failure with reduced ejection fraction. The company has received import and market permission from DCGI in Form CT-20 (Marketing Authorisation- Additional Indication). The...